Pangaea Express: Ontario Lists Inflectra @ 56% of Brand Price!

March 1, 2016

In the most recent Ontario Drug Benefit Formulary Summary of Changes, Hospira’s subsequent entry biologic (SEB), INFLECTRA (infliximab) received listing for the following indications:

  • Moderate to severe rheumatoid arthritis in patients who have severe active disease
  • For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease
  • For the treatment of psoriatic arthritis in patients who have severe active disease
  • For the treatment of severe plaque psoriasis

The listing will become effective Feb 25th 2016 and Inflectra will be reimbursed at a cost of $525.00 per 100mg/Vial Inj Pd-Vial Pk. This price of $525 is 56% of the price of the original biologic, Remicade. For more information, click here.

Currently, the price of Inflectra listed on RAMQ is $650 per 100mg/ vial. ( 70% of Brand ) As per the “most favoured nation” clause, Hospira will now need to lower its price to that of Ontario of $525.00.

Note: Health Canada had issued an NOC for Inflectra for 4 of the 9 indications granted to Remicade. Both RAMQ and the ODB are only reimbursing for these 4 indications.

Stay tuned for further details, and for more information contact Joe Knott, Managing Director, The Pangaea Group